I. Campbell et al., Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth, CANC GENE T, 7(1), 2000, pp. 37-44
The immune system confers protection against a variety of pathogens and con
tributes to the destruction of neoplastic cells. Foreign major histocompati
bility complex (MHC) protein serves as a potent stimulus to the immune syst
em. In this report, a mouse H-2K(b) gene was introduced into two poorly imm
unogenic tumor cell lines, a mouse colonic carcinoma cell line, MCA-26 (H-2
K-d), and a rat mammalian carcinoma cell line, LN-4, in an effort to stimu
late tumor rejection. Our results showed that the expression of xenogeneic
MHC class I antigen completely abolished the LN-4 tumorigenicity in rats, w
hereas the expression of allogeneic MHC class I antigen only partially redu
ced the MCA-26 tumorigenicity in mice. Rats with tumor regression of LN-4/H
-2K(b) developed a T helper type 1-dominant response, whereas rats with LN-
4 tumor growth developed a T helper type 2-dominant response. The immunized
rats that experienced LN-4/H-2Kb tumor regression further developed protec
tive immunity against a subsequent challenge of LN-4 cells. This protective
immunity was mediated by the LN-4 tumor-specific cellular immune response
against both the transduced and the parental LN-4 cells. Recombinant adenov
iral vectors are highly efficient at in vitro and in vivo gene delivery. Th
e LN4 cells transfected with the recombinant adenovirus AdV-H-2K(b) in vitr
o expressed the cell surface H-2K(b) molecule by fluorescence-activated cel
l sorter analysis. Adenovirus-mediated H-2K(b) gene transfer in vivo can fu
rther significantly inhibit pre-established LN-4 tumors. Those rats with co
mplete tumor regression further developed protective immunity against the s
ubsequent challenge of a parental LN-4 tumor. Therefore, our study indicate
s that the adenovirus-mediated transfer of xenogeneic MHC class I gene may
be an effective alternative to the current protocol of cancer gene therapy
in which the allogeneic MHC class I gene is used.